Metastatic Secondary Fibrosarcoma of Bone Responsive to Repeated
Courses of Ifosfamide and Associated With Hypoglycemia by Bouttell, Elaine S. et al.
CASE REPORT
Metastatic secondary fibrosarcoma of bone responsive to repeated
courses of ifosfamide and associated with hypoglycemia
ELAINE S. BOUTTELL
1, N. WILSON RODGER
2 & VIVIEN H.C. BRAMWELL
1
1Department of Medical Oncology, London Regional Cancer Centre &
2Division of Endocrinology, Department of
Medicine, St. Joseph’s Hospital, London, Ontario, Canada
Abstract
We present a case of a 40-year-old man with secondary fibrosarcoma of bone, arising from a non-ossifying fibroma. He
subsequently developed metastatic disease that responded to four successive chemotherapy courses, the last three using the
same dose/schedule of single agent ifosfamide. Eventual rapid progression of a huge intra-abdominal mass was associated
with the syndrome of extrapancreatic tumour hypoglycemia (EPTH). The clinicopathological behaviour of fibrosarcoma of
bone, and the mechanism of EPTH are discussed.
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Introduction
Fibrosarcoma arising from the medullary, or less
commonly, from the periosteal region of bone,
represents only 5% of the primary malignant
tumours of bone.
1–3 These lesions may also develop
secondary to previous radiation, or arise from pre-
existing benign conditions such as fibrous dysplasia,
Paget’s disease, bone infarct or cyst, osteomyelitis,
and giant-cell tumour of bone.
1–3 Fibrosarcoma of
bone has the same histological features as soft tissue
fibrosarcoma, including spindle shaped tumour cells
and interlacing bundles of collagen fibres without
any other type of histological differentiation such as
cartilage or bone formation.
1–4
The syndrome of extrapancreatic tumour hypogly-
cemia (EPTH) was described in 1930, in a patient
with hypoglycemia in association with a large
fibrosarcoma.
5 This syndrome is well recognized in
patients with sarcoma, as well as other non-islet cell
tumours of mesodermal or epithelial origin.
6 Such
tumours may be benign or malignant, but are often
slow growing and very large.
1 The mechanism is felt
to be related to the production of insulin-like growth
factor-II (IGF-II) by the tumour.
7
We present an unusual case of a man with
fibrosarcoma showing prolonged and repeated
responses to treatment with single agent ifosfamide
for metastatic disease. Toward the end of his life,
rapid tumour progression with the development of
massive intra-abdominal disease was associated with
severe hypoglycemia requiring treatment with a
glucagon infusion to maintain his blood glucose
level in the normal range.
Case report
A 40-year-old man required open reduction internal
fixation for a pathological fracture of the distal right
femur after a fall in October 1994. The pathology
was consistent with a benign non-ossifying fibroma.
In February 1995, the patient noted right leg pain
and edema, and surgery was scheduled for removal
of a compression screw from the supracondylar
fixation device. At surgery, tumour was found in
the surrounding soft tissue. The pathology revealed
evolution of the lesion to a low grade fibrosarcoma of
bone extending into the surrounding soft tissue.
The patient was evaluated at the London Regional
Cancer Centre in June of 1995. At that time, there
was a firm non-tender mass in the right thigh
with wasting of the quadriceps and gastrocnemius.
A radiograph of the right femur showed the previous
pathological fracture site, side plate and screws with
mottled bone density, lytic lesions and sclerosis at
the distal end. A periosteal mass extending into soft
tissues was present. Magnetic resonance imaging
(MRI) of the right leg revealed a mass in the right
biceps femora measuring 12 10 12.5cm and a
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intermedius measuring 3.8 3.8 3.5cm. A bone
scan showed increased tracer uptake throughout the
distal 3/4 of the right femur. Although increased
uptake was alsopresent in the right 8th and 9th ribs
anteriorly, and a left rib posteriorly, radiographs of
the ribs were normal. Chest radiograph (CXR)
showed multiple calcified granulomata, unchanged
from October 1994. The benign appearance of these
lesions was confirmed on computed tomography
(CT) scan of the thorax. A right above-knee ampu-
tation was performed in August 1995. Pathology
review by an experienced sarcoma pathologist
described a fibrosarcoma grade II/IV, with more
aggressive histological features than seen in the bone
tumour initially resected in October 1994. The
resection margins were clear and no vascular inva-
sionwasidentified.Adjuvanttreatmentwasnotgiven.
The patient was well until August 1996 when a fall
resulted in a pathological fracture of the surgical neck
of the right humerus. CXR showed multiple new
bilateral pulmonary nodules as well as the previously
noted calcified granulomata. Pulmonary metastases
were confirmed on CT scan of the thorax. A bone
scan revealed increased tracer uptake in the inter-
trochanteric region of the right femur, 7th left rib
anteriorly, proximal right humerus and humeral
head, and in the left femur from the intertrochanteric
region to the mid-shaft. MRI of the pelvis showed a
central pelvic soft tissue mass measuring 10 11cm,
and a smaller 1 1.5-cm mass in the right ischium.
The patient was treated with palliative radiotherapy
(20 Gy in five fractions) to the right shoulder but
soon after developed symptomatic epidural cord
compression at T5, and received palliative radio-
therapy from T3 to T7, with symptomatic improve-
ment. He then received seven cycles of doxorubicin
75mg/m
2 intravenously (i.v.) every 3 weeks from
October 1996 to March 1997, at which time the
total cumulative dose of doxorubicin given was
525 mg/m
2. He achieved a partial response with a
50% decrease in his pulmonary metastases and
significant shrinkage of the pelvic masses.
He remained well off treatment until August
1997 when he developed significant neck pain and
received palliative radiotherapy to a left paraspinal
soft tissue mass at the C3 level. There was progres-
sion of lung and intra-abdominal/pelvic metastases
and in September 1997 he began treatment with
ifosfamide 5g/m
2 24-h infusion given with hydration
and Mesna every 3 weeks. He completed 12 cycles
in May 1998, again achieving a partial response in
the pulmonary metastases, as well as shrinkage of the
intra-abdominal/pelvic masses. He was subsequently
followed off treatment.
In November 1998, the patient presented with a
new soft tissue mass in the right anterior chest wall
and progression of pulmonary metastases. It had
been 6 months since completion of his first course of
ifosfamide, and treatment was re-instituted using the
same regimen. Twelve more cycles of ifosfamide
were completed in August 1999, with partial
response, and he was again followed off treatment.
In January 2000, the patient developed chest wall
pain secondary to recurrence of the right anterior
chest wall mass. There was also progression of the
pulmonary metastases on CXR. A third course of
ifosfamide was instituted. In October 2000, he had
completed 11 more cycles, with a further partial
response of the chest wall mass and pulmonary
metastases. However, the following month he pre-
sented with new left lower abdominal pain and a
palpable pelvic mass. A CT scan revealed multiple
intra-abdominal soft tissue masses although no liver
metastases, lytic lesions of the right hemipelvis and
proximal femur, and a soft tissue mass in the right
upper thigh. The lung metastases had not pro-
gressed. A biopsy of the left pelvic mass was arranged
to rule out a second primary malignancy due to the
unusual development of increasing abdominal
masses without progression of pulmonary metas-
tases. The pathology was consistent with myxoid
spindle cell sarcoma.
On the day of the biopsy, the patient became pale
and diaphoretic and experienced a syncopal episode.
His blood glucose was 1.5mmol/l (normal range
3.4–11.0mmol/l). He received intravenous dextrose
and was admitted toho spital. There was noevidence
of infection. He was started on a diet of frequent
meals (q4h) toavo id recurrent hypo glycemia.
Investigations revealed normal liver function, an
appropriately low insulin level of <2.0mU/l
(normal <17.0mU/l), and low C-peptide level of
61pmol/l (normal range 166–990pmol/l), with an
appropriately elevated serum cortisol level of
968nmol/l (normal range 119–618nmol/l). Insulin-
like growth factor I (IGF-I) level was normal at
137mg/l (normal range 75–306mg/l). Insulin-like
growth factor II (IGF -II) level was measured using
a two-site immunoradiometric assay (Diagnostic
Systems Laboratories Inc., Webster, TX). It was
found to be normal at 699ng/ml (normal range 519–
1067ng/ml) and was 766ng/ml on repeat testing.
Total parenteral nutrition to supplement his oral
intake, as well as intermittent boluses of intravenous
dextrose were required to maintain his blood glucose
level over 3.0mmol/l. Later, the addition of a
glucagon infusion was implemented to maintain his
blood glucose in the normal range. In an attempt to
control the disease, treatment with dacarbazine
1000mg/m
2 was initiated. However, his abdominal
mass continued to progress rapidly and he died
2 weeks later.
Discussion
Primary fibrosarcoma of bone is recognised as an
entity distinct from soft tissue fibrosarcoma and
tends to carry a poorer prognosis.
2,3 However,
these neoplasms share pathological features of
82 E.S. Bouttell et al.spindle-shaped tumour cells with interlacing bundles
of collagen fibres without osseous or cartilagenous
differentiation.
1–4 In Broder’s grading system, well
and moderately differentiated tumours correspond to
grades I and II, respectively, while grades III and IV
refer to high grade, poorly differentiated tumours.
4
Fibrosarcoma of bone exhibits a predilection for long
tubular bones, especially around the knee in the
distal femur and proximal tibia. However, fibrosar-
comas can also occur in the humerus, as well as in
the bones of the axial skeleton.
2–4 Patients are
usually in their third to sixth decade of life, most
commonly present with pain, and up to one-third
may develop a pathological fracture.
2 An associated
soft tissue mass is present in 85% of cases.
2 The
radiographic appearance of high grade lesions is
often a patchy lytic ‘moth-eaten’ pattern which is
poorly marginated.
1–4
The 5-year overall survival rate for primary
fibrosarcoma of bone is 34–40%, although lesions
that are limited to bone carry a better prognosis (64%
10-year overall survival) compared to those with soft
tissue invasion (13% 10-year overall survival).
2,4
Limb-salvage procedures result in the same overall
survival rate as amputations as long as wide resection
margins are achieved.
4 Adjuvant radiation therapy
may reduce the high risk of local recurrence
following excision with positive margins; however,
overall survival remains poor in this setting.
3
Adjuvant chemotherapy has an established role in
osteosarcomas and may have similar efficacy in mali-
gnant fibrous histiocytoma of bone (MFH-B).
8,9
However, its role in the rare entity of fibrosarcoma
of bone is unknown. For soft tissue sarcomas
(STS), adjuvant doxorubicin and/or ifosfamide may
also have benefits for large, high grade tumours,
especially of the extremities, but this is more
controversial.
10
Multivariate analyses of clinicopathological series
of primary fibrosarcoma of bone, have shown that age
greater than 40 years, tumour in the axial skeleton,
high tumour grade, and positive resection marginsare
all risk factors for disease recurrence and lower overall
survival.
2,3 Fibrosarcoma spreads hematogenously,
with the most frequent sites of metastases being lung
and bone.
1–3 Pulmonary metastases represent the
leading cause of death in sarcoma. Complete resec-
tion of metastatic sites in unselected soft tissue and
bone sarcomas may result in an overall 5-year survival
rate of 15–38%.
2,11 However, as in our patient’s case,
unresectable multiple or bilateral pulmonary metas-
tases are common.
Many studies have shown that metastases to lung
and soft tissue are more responsive to chemotherapy
than metastatic disease in liver and bone. In meta-
static STS, the most active single agents include
doxorubicin, ifosfamide, and dacarbazine, with
reported response rates of 26, 18–21 and 16%,
respectively.
12 Definitive evidence favouring combi-
nation chemotherapy over the use of single agents is
not available. Many combinations show an improve-
ment in response rate at the expense of significantly
increased toxicity without an increase in overall
survival.
12–14 It is unknown whether fibrosarcomas
originating in bone are more responsive to regimens
active in bone sarcomas (osteosarcoma or MFH-B)
or STS. Because of this uncertainty we chose to treat
our patient with consecutive single agents (doxo-
rubicin and ifosfamide) that have documented
activity in both bone and soft tissue sarcomas. To
our knowledge, there has not been a previous report
of a patient with metastatic fibrosarcoma of bone who
has shown such repeated and prolonged responses to
treatment with single agent ifosfamide.
In a patient receiving chemotherapy for an intra-
abdominal malignancy and presenting with hypogly-
cemia, serious treatable causes, such as abdominal
sepsis, should be excluded. Chronic renal or liver
disease, and less commonly, deficiency of counter-
regulatory hormones should be considered. The
mechanism of hypoglycemia associated with non-
islet cell tumours has puzzled many since its
description by Nadler and Wolfer in 1929, and by
Doege in 1930.
5,15 Extrapancreatic tumour hypogly-
cemia (EPTH) is characterised by fasting hypoglyce-
mia accompanied by symptoms of neuroglycopenia.
Associated metabolic features are similar to those
seen with increased insulin activity, including inhibi-
tion of hepatic glycogenolysis and gluconeogenesis,
inhibition of lipolysis, and increased peripheral
glucose consumption, partly by the tumour itself,
but mainly due toincreased gluco se uptake by
skeletal muscle.
16,17 These features occur with low
circulating insulin levels and inhibition of the
counter-regulatory mechanism of growth hormone
secretion.
7,18 As a result, insulin-like growth factors
capable of stimulating insulin receptors were felt to be
the most likely candidates as the cause of EPTH.
However, IGF-I levels are consistently suppressed in
these patients and many early studies showed IGF-II
levels were in the normal range when measured by
radioreceptor or radioimmunoassays (RIA), such as
the assay used for our patient.
18–21 There have been a
number of hypotheses, but the definitive explanation
for this is uncertain.
In 1988, Daughaday et al. reported a case of a
patient with leiomyosarcoma associated with EPTH
whose serum IGF-II levels were normal using radio-
receptor assay and RIA. However, when serum was
acidified and fractionated using a BioGel P-60
column, 70% of the total IGF-II eluted was in the
high molecular weight range (big IGF-II), whereas
most of the IGF-II in normal serum was of lower
molecular weight. They tested tumour samples using
this same method and showed that 77% of the total
IGF-II consisted of the high molecular weight form.
7
Others have found that these tumours contain greater
than 100 times the amount of IGF-II mRNA found
in normal human liver or adipose tissue.
22,23 Both
IGF-I and II are bound to specific high molecular
Metastatic secondary fibrosarcoma 83weight carrier proteins in the circulation, with less
than 2% found in the free form.
24 In normal serum,
70–80% of IGF-I and II are found within a 150-kDa
complex which is a trimer consisting of IGF, IGF
binding protein-3 (IGFBP-3), and an acid-labile
glycoprotein (a-subunit).
18,24,25 Normal levels of
both IGFBP-3 and the a-subunit are dependent on
growth hormone secretion.
18 This large complex is
sequestered in the vascular compartment by the
capillary barrier, is not bioavailable to tissues, and
thus has a long serum half-life of 12–16h.
26
Normally, a smaller proportion (20–30%) of IGF-II
is present in a smaller 50-kDa complex that can cross
the capillary barrier and sois the main fo rm that is
bioavailable to tissues. This complex contains IGF
bound mainly to IGFBP-2 and some IGFBP-3, and
is more rapidly cleared from the circulation, with a
half-life of 30min.
21,26 In patients with EPTH, the
150-kDa complex may be reduced due to inhibition
of growth hormone by IGF resulting in decreased
synthesis of the IGFBP-3 and the a-subunit. The
IGF-II content of the 50-kDa complex is then
increased, which may account for its increased
bioavailability to tissues despite normal levels of
total IGF-II.
18,27
Continuous intravenous glucagon infusion for the
treatment of EPTH was first described by Samaan
et al.
28 However, prior to that, intramuscular injec-
tion of zinc glucagon had been used in the treatment
tumour-induced hypoglycemia.
16,29 Glucagon stimu-
lates hepatic glucose production by glycogenolysis
and gluconeogenesis. However, when hypoglycemia
is due to liver metastases with hepatic failure, poor
glycogen reserve may result in failure to respond to
glucagon administration.
18 If normalisation of blood
glucose levels is achieved, continuous glucagon
infusion using a portable pump can be administered
on an outpatient basis.
18 However, tumor eradication
by surgery, radiotherapy or chemotherapy is crucial
for long-term control of glucose levels. In our patient,
the syndrome of EPTH was associated with a fifth
metastatic relapse that occurred after responses to
four prolonged courses of chemotherapy (three to the
same drug). Emergence of the syndrome seemed to
be associated with aggressive drug-resistant disease
leading tothe patient’s early demise.
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